Filtered By:
Infectious Disease: Hepatitis C
This page shows you your search results in order of date.
Order by Relevance | Date
Total 14890 results found since Jan 2013.
Stemness markers in hepatocellular carcinoma of Eastern vs. Western population: Etiology matters?
Ann Hepatol. 2023 Sep 19:101153. doi: 10.1016/j.aohep.2023.101153. Online ahead of print.ABSTRACTHepatocellular carcinoma (HCC) is one of the most common cancers with a high mortality rate. HCC development is associated with its underlying etiologies, mostly caused by infection of chronic hepatitis B virus (HBV) and hepatitis C virus (HCV), alcohol, non-alcoholic fatty liver disease, and exposure to aflatoxins. These variables, together with human genetic susceptibility, contribute to HCC molecular heterogeneity, including the cellular level. HCC initiation, tumor recurrence, and drug resistance rates have been attributed ...
Source: Annals of Hepatology - September 21, 2023 Category: Gastroenterology Authors: Caecilia Sukowati Korri El-Khobar Chyntia Olivia Maurine Jasirwan Juferdy Kurniawan Rino Alvani Gani Source Type: research
Analysis of the mechanism of action of Euphorbia fischeriana Steud on cirrhosis based on network pharmacology
This study aimed to employ network pharmacology to elucidate the mechanism by which Euphorbia fischeriana Steud (EFS) exhibits the efficacy on cirrhosis. The compounds and targets of EFS were retrieved from Traditional Chinese Medicine Integrated Database and Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP). Next, these compounds and targets were analyzed based on protein-protein interaction (PPI) network. Furthermore, Kyoto Encyclopedia of Genes and Genomes (KEGG) signaling network was established based on KEGG database. We constructed a compound-compound target-intersection target-...
Source: Atherosclerosis - September 15, 2023 Category: Cardiology Authors: Lu Liu Yinliang Xu Liu Yang Zhenzhong Jiang Xiaoyan Li Source Type: research
MicroRNA signature from extracellular vesicles of HCV/HIV co-infected individuals differs from HCV mono-infected
J Mol Med (Berl). 2023 Sep 14. doi: 10.1007/s00109-023-02367-8. Online ahead of print.ABSTRACTHepatitis C virus (HCV) coinfection with human immunodeficiency virus (HIV) has a detrimental impact on disease progression. Increasing evidence points to extracellular vesicles (EVs) as important players of the host-viral cross-talk. The microRNAs (miRNAs), as essential components of EVs cargo, are key regulators of normal cellular processes and also promote viral replication, viral pathogenesis, and disease progression. We aimed to characterize the plasma-derived EVs miRNA signature of chronic HCV infected and HIV coinfected pat...
Source: Molecular Medicine - September 13, 2023 Category: Molecular Biology Authors: Victoria Cairoli Daniel Valle-Millares Mar ía C Terrón-Orellano Daniel Luque Pablo Ryan Lourdes Dominguez Luz Mart ín-Carbonero Ignacio De Los Santos Elena De Matteo Beatriz Ameigeiras Ver ónica Briz Paola Casciato Mar ía Victoria Preciado Pamela Val Source Type: research
A case of difficult-to-diagnose hepatic reactive lymphoid hyperplasia finally diagnosed by using PCR analysis of IgH-gene rearrangements: a case report
AbstractReactive lymphoid hyperplasia (RLH) of the liver is extremely rare. Despite advancements in diagnostic imaging technology, it is still difficult to distinguish from hepatocellular carcinoma (HCC). Herein, we present a case of hepatic RLH mimicking HCC that was postoperatively diagnosed using several imaging modalities. A 78-year-old female was referred to our hospital with a positive hepatitis C virus antibody (HCV Ab) test. Ultrasonography revealed a 13 mm isoechoic lesion in segment 8 of the liver. Contrast-enhanced computed tomography (CE-CT) demonstrated arterial hyperintensity and washout during the later ph...
Source: International Cancer Conference Journal - September 5, 2023 Category: Cancer & Oncology Source Type: research
Transcription Factor JunB Suppresses Hepatitis C Virus Replication
Kobe J Med Sci. 2023 Aug 31;69(3):E86-E95.ABSTRACTWe previously reported that hepatitis C virus (HCV) infection activates the reactive oxygen species (ROS)/c-Jun N-terminal kinase (JNK) signaling pathway. Activation of JNK contributes to the development of liver diseases, including metabolic disorders, steatosis, liver cirrhosis and hepatocellular carcinoma. JNK is known to have numerous target genes, including JunB, a member of activator protein-1 transcription factor family. However, the roles of JunB in the HCV life cycle and HCV-associated pathogenesis remain unclear. To clarify a physiological role of JunB in HCV infe...
Source: Kobe J Med Sci - September 4, 2023 Category: General Medicine Authors: Adi Ariffianto Lin Deng Saki Harada Yujiao Liang Chieko Matsui Takayuki Abe Ikuo Shoji Source Type: research
A therapeutic dose and its pharmacokinetics of ropeginterferon Alfa-2b for hepatitis C treatment
CONCLUSION: Ropeginterferon alfa-2b at 400 μg led to PK exposures associated with safety and notable clinical activity in patients with chronic HCV. This study suggests that ropeginterferon alfa-2b at 400 μg is an acceptable dosing regimen for treating chronic HCV and also provides supporting data for the clinical use of ropeginterferon alfa-2b at a higher starting dose for other indications.PMID:37666718 | DOI:10.1016/j.jfma.2023.08.023
Source: J Formos Med Assoc - September 4, 2023 Category: General Medicine Authors: Ching-Chu Lo Wan-Long Chuang Hsing-Tao Kuo Wei-Ming Chen Albert Qin Chan-Yen Tsai Yi-Wen Huang Chi-Yi Chen Source Type: research
Transcription Factor JunB Suppresses Hepatitis C Virus Replication
Kobe J Med Sci. 2023 Aug 31;69(3):E86-E95.ABSTRACTWe previously reported that hepatitis C virus (HCV) infection activates the reactive oxygen species (ROS)/c-Jun N-terminal kinase (JNK) signaling pathway. Activation of JNK contributes to the development of liver diseases, including metabolic disorders, steatosis, liver cirrhosis and hepatocellular carcinoma. JNK is known to have numerous target genes, including JunB, a member of activator protein-1 transcription factor family. However, the roles of JunB in the HCV life cycle and HCV-associated pathogenesis remain unclear. To clarify a physiological role of JunB in HCV infe...
Source: Kobe J Med Sci - September 4, 2023 Category: General Medicine Authors: Adi Ariffianto Lin Deng Saki Harada Yujiao Liang Chieko Matsui Takayuki Abe Ikuo Shoji Source Type: research
A therapeutic dose and its pharmacokinetics of ropeginterferon Alfa-2b for hepatitis C treatment
CONCLUSION: Ropeginterferon alfa-2b at 400 μg led to PK exposures associated with safety and notable clinical activity in patients with chronic HCV. This study suggests that ropeginterferon alfa-2b at 400 μg is an acceptable dosing regimen for treating chronic HCV and also provides supporting data for the clinical use of ropeginterferon alfa-2b at a higher starting dose for other indications.PMID:37666718 | DOI:10.1016/j.jfma.2023.08.023
Source: J Formos Med Assoc - September 4, 2023 Category: General Medicine Authors: Ching-Chu Lo Wan-Long Chuang Hsing-Tao Kuo Wei-Ming Chen Albert Qin Chan-Yen Tsai Yi-Wen Huang Chi-Yi Chen Source Type: research
Transcription Factor JunB Suppresses Hepatitis C Virus Replication
Kobe J Med Sci. 2023 Aug 31;69(3):E86-E95.ABSTRACTWe previously reported that hepatitis C virus (HCV) infection activates the reactive oxygen species (ROS)/c-Jun N-terminal kinase (JNK) signaling pathway. Activation of JNK contributes to the development of liver diseases, including metabolic disorders, steatosis, liver cirrhosis and hepatocellular carcinoma. JNK is known to have numerous target genes, including JunB, a member of activator protein-1 transcription factor family. However, the roles of JunB in the HCV life cycle and HCV-associated pathogenesis remain unclear. To clarify a physiological role of JunB in HCV infe...
Source: Kobe J Med Sci - September 4, 2023 Category: General Medicine Authors: Adi Ariffianto Lin Deng Saki Harada Yujiao Liang Chieko Matsui Takayuki Abe Ikuo Shoji Source Type: research
A therapeutic dose and its pharmacokinetics of ropeginterferon Alfa-2b for hepatitis C treatment
CONCLUSION: Ropeginterferon alfa-2b at 400 μg led to PK exposures associated with safety and notable clinical activity in patients with chronic HCV. This study suggests that ropeginterferon alfa-2b at 400 μg is an acceptable dosing regimen for treating chronic HCV and also provides supporting data for the clinical use of ropeginterferon alfa-2b at a higher starting dose for other indications.PMID:37666718 | DOI:10.1016/j.jfma.2023.08.023
Source: Methods of Information in Medicine - September 4, 2023 Category: Information Technology Authors: Ching-Chu Lo Wan-Long Chuang Hsing-Tao Kuo Wei-Ming Chen Albert Qin Chan-Yen Tsai Yi-Wen Huang Chi-Yi Chen Source Type: research
Transcription Factor JunB Suppresses Hepatitis C Virus Replication
Kobe J Med Sci. 2023 Aug 31;69(3):E86-E95.ABSTRACTWe previously reported that hepatitis C virus (HCV) infection activates the reactive oxygen species (ROS)/c-Jun N-terminal kinase (JNK) signaling pathway. Activation of JNK contributes to the development of liver diseases, including metabolic disorders, steatosis, liver cirrhosis and hepatocellular carcinoma. JNK is known to have numerous target genes, including JunB, a member of activator protein-1 transcription factor family. However, the roles of JunB in the HCV life cycle and HCV-associated pathogenesis remain unclear. To clarify a physiological role of JunB in HCV infe...
Source: Kobe J Med Sci - September 4, 2023 Category: General Medicine Authors: Adi Ariffianto Lin Deng Saki Harada Yujiao Liang Chieko Matsui Takayuki Abe Ikuo Shoji Source Type: research
A therapeutic dose and its pharmacokinetics of ropeginterferon Alfa-2b for hepatitis C treatment
CONCLUSION: Ropeginterferon alfa-2b at 400 μg led to PK exposures associated with safety and notable clinical activity in patients with chronic HCV. This study suggests that ropeginterferon alfa-2b at 400 μg is an acceptable dosing regimen for treating chronic HCV and also provides supporting data for the clinical use of ropeginterferon alfa-2b at a higher starting dose for other indications.PMID:37666718 | DOI:10.1016/j.jfma.2023.08.023
Source: Methods of Information in Medicine - September 4, 2023 Category: Information Technology Authors: Ching-Chu Lo Wan-Long Chuang Hsing-Tao Kuo Wei-Ming Chen Albert Qin Chan-Yen Tsai Yi-Wen Huang Chi-Yi Chen Source Type: research
Transcription Factor JunB Suppresses Hepatitis C Virus Replication
Kobe J Med Sci. 2023 Aug 31;69(3):E86-E95.ABSTRACTWe previously reported that hepatitis C virus (HCV) infection activates the reactive oxygen species (ROS)/c-Jun N-terminal kinase (JNK) signaling pathway. Activation of JNK contributes to the development of liver diseases, including metabolic disorders, steatosis, liver cirrhosis and hepatocellular carcinoma. JNK is known to have numerous target genes, including JunB, a member of activator protein-1 transcription factor family. However, the roles of JunB in the HCV life cycle and HCV-associated pathogenesis remain unclear. To clarify a physiological role of JunB in HCV infe...
Source: Kobe J Med Sci - September 4, 2023 Category: General Medicine Authors: Adi Ariffianto Lin Deng Saki Harada Yujiao Liang Chieko Matsui Takayuki Abe Ikuo Shoji Source Type: research
